Effect of Doxorubicin Combined with Ipratropium Bromide on Pulmonary Function Indexes in the Treatment of Chronic Obstructive Pulmonary Disease

  • Rong Fan Jingzhou First People's Hospital
  • Wei Xiao Jingzhou First People's Hospital
  • Weihua Hu Jingzhou First People's Hospital
  • Zhu Wu Jingzhou First People's Hospital
DOI: https://doi.org/10.18686/aem.v12i1.349
Keywords: Chronic Obstructive Pulmonary Disease, Doxorubicin, Ipratropium Bromide, Pulmonary Function, Total Effective Rate

Abstract

Objective: To observe the effect of different methods in the treatment of chronic obstructive pulmonary (COPD) disease. Methods: 86 COPD patients attending the clinic from 2020.7 to 2022.11 were divided into groups I and II according to the envelope method, 43 cases each were treated with theophylline extended-release tablets and group II was treated with ipratropium bromide, the lung function indexes of each group were tested and the total effective rate was calculated and compared between groups. Results: At the end of the treatment course, FEV1, FVC and FEV1/FVC levels in group II were higher than those in group I, and the difference reached a significant level (P < 0.05). The total effective rate in group I was 74.42%, which was lower than that in group II, which was 95.35%, forming a significant difference (P < 0.05). Conclusion: Treatment with doxorubicin combined with ipratropium bromide for those with COPD is effective and worthy of popular application.

References

[1] Deng ZG. Effectiveness of theophylline extended-release tablets in combination with inhaled ipratropium bromide in the treatment of chronic obstructive pulmonary disease[J]. Northern Pharmacology, 2022, 19(03): 160-162.

[2] Shen WH. Analysis of the efficacy of tonifying Zhong Yi Qi Tang combined with ipratropium bromide in the treatment of patients with chronic obstructive pulmonary disease [J]. Gansu Science and Technology, 2021,37(19):185-187.

[3] Shi HY. Efficacy of budesonide combined with ipratropium bromide in the treatment of chronic obstructive pulmonary disease[J]. Electronic Journal of Clinical Medicine Literature,2020,7(35):61-62.
Published
2023-03-21
Issue
Vol 12, No 1(2023)
Section
Original Research Article

Copyright (c) 2023 Rong Fan, Wei Xiao, Weihua Hu, Zhu Wu

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.